Steven Gannon - 05 Jun 2025 Form 4 Insider Report for Xenon Pharmaceuticals Inc. (XENE)

Role
Director
Signature
/s/ Nathaniel Adams, Attorney-in-fact
Issuer symbol
XENE
Transactions as of
05 Jun 2025
Net transactions value
-$91.44
Form type
4
Filing time
06 Jun 2025, 17:58:57 UTC
Previous filing
16 May 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
GANNON STEVEN Director 3650 GILMORE WAY, BURNABY, BRITISH COLUMBIA, CANADA /s/ Nathaniel Adams, Attorney-in-fact 06 Jun 2025 0001643085

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XENE Common Shares Sale $91.44 -3 -0.04% $30.48 7,141 05 Jun 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XENE Share Option (Right to Buy) Award $0 +17,012 $0.000000 17,012 05 Jun 2025 Common Shares 17,012 $30.73 Direct F2
transaction XENE Restricted Share Units Award $0 +2,645 $0.000000 2,645 05 Jun 2025 Common Shares 2,645 $0.000000 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares automatically sold in payment of transfer fee for transfer of shares to an alternate brokerage account.
F2 Vesting 100% on the earlier of (i) June 4, 2026 or (ii) the day before the date of the issuer's 2026 annual meeting of shareholders.
F3 Each restricted share unit represents a contingent right to receive one Common Share vesting 100% on the earlier of (i) June 4, 2026 or (ii) the day before the date of the issuer's 2026 annual meeting of shareholders.